Ensysce acquires Cy Biopharma and secures up to $77 million to advance CRPS therapy CY200
- nuaxia
- 8월 7일
- 3분 분량
The stock-for-stock acquisition adds a clinical-stage neuroplastogenic pain programme to Ensysce’s pipeline, with concurrent financing expected to fund CY200 through Phase II proof-of-concept data and towards registrational development.
Ensysce Biosciences has completed the acquisition of Cy Biopharma in a stock-for-stock merger, adding CY200, a clinical-stage neuroplastogenic therapy with FDA Orphan Drug Designation for complex regional pain syndrome (CRPS) type 1, to its pain portfolio.
The transaction is accompanied by $17.1 million of Cy Biopharma cash and up to approximately $60.1 million in new private financing, including a $38.6 million milestone-dependent second tranche, providing potential funding of up to approximately $77 million to advance CY200.
Field | Content |
Alert Type | Deal |
Companies | Ensysce Biosciences; Cy Biopharma |
Deal Type | Acquisition through stock-for-stock merger, accompanied by private placement financing |
Asset or Company | Cy Biopharma and its lead candidate CY200 |
Therapy Area(s) | Neurology; Pain; Complex regional pain syndrome |
Technology or Modality | Neuroplastogenic therapy |
Deal Value | The acquisition consideration consists of 282,122 shares of Ensysce Series C preferred stock, representing 282.1 million shares on an as-converted basis. Separately, the transaction brings $17.1 million of Cy Biopharma cash from pre-acquisition financing and is accompanied by approximately $43 million of private placement financing across two tranches: approximately $21.5 million at initial closing and up to $38.6 million at the milestone closing, resulting in up to approximately $77 million of potential funding when Cy Biopharma’s cash is included. The second financing tranche is contingent on achievement of a clinical trial milestone. (Newswire) |
Development Stage | Clinical stage; CY200 is being advanced towards a randomised Phase II trial in CRPS type 1. |
Geography | United States |
What Happened | On 6 August 2026, Ensysce Biosciences announced completion of its acquisition of privately held Cy Biopharma through a stock-for-stock merger. Cy Biopharma’s former equityholders received Series C preferred shares and are expected to own approximately 74.94% of the combined company on a fully diluted basis following stockholder approval of their conversion, excluding shares potentially issued in the milestone financing. Concurrently, Ensysce entered a private placement expected to provide approximately $21.5 million initially and up to another $38.6 million following achievement of a clinical trial milestone; Cy Biopharma also brought $17.1 million of cash from pre-acquisition financing. (Newswire) |
Why It Matters | The acquisition expands Ensysce beyond its existing opioid safety programmes into neuroplastogenic treatments for complex pain and gives the company control of CY200, which has FDA Orphan Drug Designation for CRPS. Importantly, the associated financing is expected to support CY200 through Phase II proof-of-concept data and preparations for registrational development, reducing the immediate financing requirement around a key clinical milestone. (Newswire) |
Supporting Context | CRPS is a severe chronic pain disorder with limited effective treatment options. Cy Biopharma is developing CY200 as an approach intended to address the underlying neurobiology of CRPS rather than solely managing symptoms, although its clinical benefit remains to be established through controlled trials. (Newswire) |
Strategic Rationale | Ensysce gains a clinical-stage programme addressing complex pain while continuing development of its existing PF614-MPAR opioid overdose-protection programme. Cy Biopharma gains access to a public-market platform and financing intended to support CY200 through its next major clinical development milestones. (Newswire) |
Potential Impact | If CY200 produces supportive Phase II results, the transaction could give Ensysce a second differentiated pain-development platform alongside its TAAP and MPAR programmes. Progress towards registrational development will depend on the clinical results, achievement of financing milestones and subsequent regulatory requirements. |
Key Takeaway | The Cy Biopharma acquisition adds a clinical-stage neuroplastogenic pain programme to Ensysce while providing potential financing through CY200’s Phase II proof-of-concept milestone. |
What to Watch | Topline results from the planned randomised Phase II CY200 trial, achievement of the clinical milestone required to unlock the second financing tranche, and Ensysce stockholder approval for conversion of the Series C preferred shares into common stock. (Newswire) |
Primary Source | |
Relevant Date | 6 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글